0A9G Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.59 |
| 52 Week High | US$5.01 |
| 52 Week Low | US$2.28 |
| Beta | 0.98 |
| 1 Month Change | -11.52% |
| 3 Month Change | -20.37% |
| 1 Year Change | -13.59% |
| 3 Year Change | 112.48% |
| 5 Year Change | n/a |
| Change since IPO | -17.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A9G | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.6% | 0.2% | 0.2% |
| 1Y | -13.6% | -11.7% | 6.3% |
Return vs Industry: 0A9G underperformed the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0A9G underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| 0A9G volatility | |
|---|---|
| 0A9G Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A9G's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A9G's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| 0A9G fundamental statistics | |
|---|---|
| Market cap | US$368.66m |
| Earnings (TTM) | -US$45.32m |
| Revenue (TTM) | US$1.00m |
368.7x
P/S Ratio-8.1x
P/E RatioIs 0A9G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A9G income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | -US$273.00k |
| Gross Profit | US$1.27m |
| Other Expenses | US$46.59m |
| Earnings | -US$45.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 127.30% |
| Net Profit Margin | -4,531.60% |
| Debt/Equity Ratio | 7.7% |
How did 0A9G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 10:10 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mereo BioPharma Group plc is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Yun Zhong | BTIG |
| Julian Harrison | BTIG |